These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31217270)

  • 21. Performance of serological and molecular tests within acute HIV infection.
    Fransen K; de Baetselier I; Rammutla E; Ahmed K; Owino F; Agingu W; Venter G; Deese J; Van Damme L; Crucitti T;
    J Clin Virol; 2017 Aug; 93():81-84. PubMed ID: 28351688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute HIV infection (AHI) in a specialized clinical setting: case-finding, description of virological, epidemiological and clinical characteristics.
    Ammassari A; Abbate I; Orchi N; Pinnetti C; Rozera G; Libertone R; Pierro P; Martini F; Puro V; Girardi E; Antinori A; Capobianchi MR
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19676. PubMed ID: 25397426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Staging of recent HIV-1 infection using Geenius rapid confirmatory assay compared to INNO-LIA, New Lav and Blot 2.2 assays.
    Tuaillon E; Sanosyan A; Pisoni A; Liscouët J; Makinson A; Perre PV
    J Clin Virol; 2017 Oct; 95():47-51. PubMed ID: 28843384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ARCHITECT® HIV Ag/Ab Combo assay: correlation of HIV-1 p24 antigen sensitivity and RNA viral load using genetically diverse virus isolates.
    Brennan CA; Yamaguchi J; Vallari A; Swanson P; Hackett JR
    J Clin Virol; 2013 Jun; 57(2):169-72. PubMed ID: 23485348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection.
    Hare CB; Pappalardo BL; Busch MP; Karlsson AC; Phelps BH; Alexander SS; Bentsen C; Ramstead CA; Nixon DF; Levy JA; Hecht FM
    Clin Infect Dis; 2006 Mar; 42(5):700-8. PubMed ID: 16447118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and Evaluation of a Modified Fourth-Generation Human Immunodeficiency Virus Enzyme Immunoassay for Cross-Sectional Incidence Estimation in Clade B Populations.
    Kirkpatrick AR; Patel EU; Celum CL; Moore RD; Blankson JN; Mehta SH; Kirk GD; Margolick JB; Quinn TC; Eshleman SH; Laeyendecker O
    AIDS Res Hum Retroviruses; 2016 Aug; 32(8):756-62. PubMed ID: 26988426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance evaluation of the Bio-Rad Geenius HIV 1/2 supplemental assay.
    Luo W; Sullivan V; Smith T; Peters PJ; Gay C; Westheimer E; Cohen SE; Owen SM; Masciotra S
    J Clin Virol; 2019 Feb; 111():24-28. PubMed ID: 30594702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of Bio-Rad HIV-1/2 Confirmatory Assay in HIV-1, HIV-2 and HIV-1/2 dually reactive patients - comparison with INNO-LIA and immunocomb discriminatory assays.
    Lindman J; Hønge BL; Kjerulff B; Medina C; da Silva ZJ; Erikstrup C; Norrgren H; Månsson F
    J Virol Methods; 2019 Jun; 268():42-47. PubMed ID: 30871983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sample-to-cutoff ratios using Architect HIV Ag/Ab Combo: The influence with the results of supplemental tests and optimal cutoff value to predict HIV infection.
    Wang L; Wang JY; Tian XD; Ruan JX; Yu Y; Yan F
    J Clin Lab Anal; 2019 Jun; 33(5):e22866. PubMed ID: 30803030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the Bio-Rad Geenius HIV 1/2 Confirmation Assay as an Alternative to Western Blot in the Korean Population: A Multi-Center Study.
    Moon HW; Huh HJ; Oh GY; Lee SG; Lee A; Yun YM; Hur M
    PLoS One; 2015; 10(9):e0139169. PubMed ID: 26422281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance of the new HIV-1/2 diagnostic algorithm in Florida's public health testing population: a review of the first five months of utilization.
    Bennett B; Neumann D; Fordan S; Villaraza R; Crowe S; Gillis L
    J Clin Virol; 2013 Dec; 58 Suppl 1():e29-33. PubMed ID: 24342476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No Time to Delay! Fiebig Stages and Referral in Acute HIV infection: Seattle Primary Infection Program Experience.
    Stekler JD; Tapia K; Maenza J; Stevens CE; Ure GA; O'Neal JD; Lane A; Mullins JI; Coombs RW; Holte S; Collier AC
    AIDS Res Hum Retroviruses; 2018 Aug; 34(8):657-666. PubMed ID: 29756456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening and diagnostic testing protocols for HIV and Syphilis infections in health care setting in Qatar: Evaluation and recommendations.
    Nasrallah GK; Al-Buainain R; Younes N; Dargham SR; Al-Sadeq DW; Elhassan M; Al-Shaar I; Yassine HM; Abu-Raddad LJ; Emara MM; Ismail A
    PLoS One; 2023; 18(2):e0278079. PubMed ID: 36749795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stability of Human Immunodeficiency Virus Serological Markers in Samples Collected as HemaSpot and Whatman 903 Dried Blood Spots.
    Manak MM; Hack HR; Shutt AL; Danboise BA; Jagodzinski LL; Peel SA
    J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30045869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Data on the relationship of signal-to-cutoff ratio of two HIV antigen/antibody combination assays to subsequent confirmation of HIV-1 infection in a low-prevalence population.
    Hodgson CK; Krasowski MD; Ford BA
    Data Brief; 2020 Aug; 31():105707. PubMed ID: 32462068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the Architect HIV Ag/Ab Combo Assay in a low-prevalence setting: The role of samples with a low S/CO ratio.
    Alonso R; Pérez-García F; Gijón P; Collazos A; Bouza E
    J Clin Virol; 2018 Jun; 103():43-47. PubMed ID: 29635210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Performance evaluation of three automated human immunodeficiency virus antigen-antibody combination immunoassays.
    Kwon JA; Yoon SY; Lee CK; Lim CS; Lee KN; Sung HJ; Brennan CA; Devare SG
    J Virol Methods; 2006 Apr; 133(1):20-6. PubMed ID: 16313975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of individuals with acute HIV-1 infection using the ARCHITECT HIV Ag/Ab Combo assay.
    Eshleman SH; Khaki L; Laeyendecker O; Piwowar-Manning E; Johnson-Lewis L; Husnik M; Koblin B; Coates T; Chesney M; Vallari A; Devare SG; Hackett J
    J Acquir Immune Defic Syndr; 2009 Sep; 52(1):121-4. PubMed ID: 19506484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of the Signal-to-Cutoff Ratio and Antigen Index from Fourth- and Fifth-Generation HIV-1/HIV-2 Antigen/Antibody Assays for the Diagnosis of Acute HIV Infection: Applicability for Real-Time Use for Immediate Initiation of Antiretroviral Therapy.
    Whitney E; Pitrak D; Beavis KG; Moore NM; Shankaran S; Abeleda AP; Schmitt J; Sha BE
    J Clin Microbiol; 2022 Dec; 60(12):e0120422. PubMed ID: 36448814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV serology false positivity among expatriates from Africa: a screening dilemma.
    Al-Kindi H; Al-Jardani A
    J Med Microbiol; 2020 Jun; 69(6):812-816. PubMed ID: 32469303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.